Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bespoke ExtractsBSPK Debt-to-Equity is -0.55 as of Sep. 2025. The stock has 3 warning signs investors should review. Among 813 Drug Manufacturers companies, Bespoke Extracts ranks worse than 123001.11% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Bespoke Extracts's Debt-to-Equity or its related term are showing as below:
BSPK'
s Debt-to-Equity Range Over the Past 10 Years
Min: -3.04 Med: -0.92 Max: 20.31
Current: -0.55
During the past 13 years, the highest Debt-to-Equity Ratio of Bespoke Extracts was 20.31. The lowest was -3.04. And the median was -0.92.
BSPK's Debt-to-Equity is not ranked
in the Drug Manufacturers industry.
Industry Median: 0.27
vs BSPK: -0.55
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Bespoke Extracts Debt-to-Equity Related Terms
Bespoke Extracts Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Bespoke Extracts's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSPK vs ZTS, UTHR, VTRS: Debt-to-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Bespoke Extracts's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bespoke Extracts Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bespoke Extracts's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Bespoke Extracts's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bespoke Extracts (BSPK) has a Debt-to-Equity of -0.55 as of Sep. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Bespoke Extracts and its competitors. According to the industry distribution chart, Bespoke Extracts ranks #999999 out of 813 companies in the Drug Manufacturers industry.
Is Bespoke Extracts' Debt-to-Equity too high?
Bespoke Extracts' current Debt-to-Equity is -0.55. Based on the distribution chart, Bespoke Extracts ranks #999999 out of 813 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Bespoke Extracts' Debt-to-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Bespoke Extracts ranks #999999 out of 813 companies for Debt-to-Equity. This places Bespoke Extracts in the lower half of its industry. The industry median Debt-to-Equity is 0.27. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.27, based on 813 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Bespoke Extracts and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bespoke Extracts's current Debt-to-Equity is -0.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bespoke Extracts stock overvalued right now?
Bespoke Extracts (BSPK) has a current Debt-to-Equity of -0.55. The current Debt-to-Equity is -0.55. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Bespoke Extracts (BSPK), the current Debt-to-Equity is -0.55 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bespoke Extracts Inc is focused on selling its proprietary line of specially-formulated, quality, hemp-derived CBD products. The company owns, manufactures, and distributes a portfolio of cannabis consumer packaged goods brands including Fresh Joints, Doobskis, DutchBlunts, and Wee Joints, to licensed marijuana dispensaries across Colorado.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSPK has been successfully added to your 
